US Advises Seniors Against Getting Chikungunya Vaccine Due to Safety Concerns
US health officials advise travelers aged 60 and above to avoid the chikungunya vaccine amid ongoing safety investigations due to potential side effects in older adults.
In recent health developments, US health authorities have issued a cautionary message to travelers aged 60 and above, recommending against receiving the chikungunya vaccine while investigations into potential side effects are ongoing. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) released notices last week concerning the vaccine, Valneva's Ixchiq, which was previously recommended for adults traveling to regions affected by chikungunya.
Chikungunya is a mosquito-borne illness endemic to tropical areas, characterized by high fever, severe joint pain, and fatigue. Despite its typically mild initial symptoms, the disease can cause prolonged joint issues and significant health problems. Annually, around 100 to 200 cases are reported in the United States among travelers returning from affected regions.
The vaccine, developed using a weakened form of the chikungunya virus, was introduced last year as a preventive measure for at-risk populations. However, recent reports have raised safety concerns, particularly regarding older adults. A review by vaccine experts revealed six cases of individuals aged 65 and above who experienced heart or brain-related symptoms shortly after vaccination. Notably, most of these individuals had preexisting health conditions. Additional similar cases have been documented internationally.
Regulatory agencies in Europe are also examining these cases as part of their review process. In response to the emerging data, US advisory panels have recommended placing a precaution on the vaccine’s use in seniors over 65. Meanwhile, another chikungunya vaccine by Bavarian Nordic, Vimkunya, remains recommended for travelers aged 12 and older, though decisions on its widespread use are yet to be finalized.
This development underscores the importance of carefully evaluating vaccine safety, especially in vulnerable populations. Travelers are advised to consult healthcare providers for personalized recommendations and remain informed about ongoing safety assessments regarding chikungunya vaccination.
Source: https://medicalxpress.com/news/2025-05-health-older-chikungunya-vaccine.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Rising Incidence of Breast Cancer Among Young Women Explained
Breast cancer rates are rising among women aged 20 to 49, driven by earlier menarche, reproductive trends, and lifestyle factors. Learn about the causes, risks, and preventative strategies.
MIND Diet May Reduce Dementia Risk Regardless of When You Start
Research shows that following the MIND diet can reduce dementia risk even if adopted later in life. The diet emphasizes brain-healthy foods like berries, leafy greens, nuts, and olive oil, supporting cognitive health across diverse populations.
Do People Truly Want to Know Their Risk of Developing Alzheimer's?
A new study explores the emotional and ethical complexities of disclosing Alzheimer's risk, revealing many individuals prefer not to know their potential future, highlighting the need for careful consideration of testing practices.